Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

被引：0
|
作者：
Hong, S. N. [1 ]
Yujin, L. [1 ]
Boram, P. [2 ]
Soon, J. Ok [3 ]
Ho, K. Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Biomed Stat Ctr, Res Inst Future Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Data Serv Team, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P353
引用
收藏
页码：I745 / I745
页数：1
相关论文
共 50 条
  • [1] Therapeutic drug monitoring in 45 children with inflammatory bowel disease on maintenance infliximab treatment
    Rolandsdotter, H.
    Marits, P.
    Sundin, U.
    Wikstrom, A. -C.
    Fagerberg, U.
    Finkel, Y.
    Eberhardson, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S363 - S364
  • [2] Proactive Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease Patients Receiving Infliximab and Biosimilars
    Aktay, Atiye
    Odolil, Abel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S21 - S21
  • [3] COST EFFECTIVENESS OF A PROACTIVE THERAPEUTIC DRUG MONITORING STRATEGY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB
    Doherty, Jayne
    Varley, Rachel
    Kennedy, Una
    Healy, Martin
    Dunne, Cara
    Maccarthy, Finbar
    Mckiernan, Susan
    Hartery, Karen
    Kevans, David
    GASTROENTEROLOGY, 2021, 160 (06) : S692 - S693
  • [4] Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab
    Doherty, J.
    Varley, R.
    Healy, M.
    Dunne, C.
    Mac Carthy, E.
    Mc Kiernan, S.
    Hartery, K.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S445 - S446
  • [5] Prospective Therapeutic Drug Monitoring to Optimizing Infliximab (IFX) Maintenance Therapy in Patients With Inflammatory Bowel Disease (IBD)
    Vaughn, Byron P.
    Martinez-Vazquez, Manuel
    Patwardhan, Vilas
    Moss, Alan C.
    Sandborn, William J.
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2014, 146 (05) : S54 - S54
  • [6] Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease
    Quera, Rodrigo
    Moreno, Mauricio
    Simian, Daniela
    Ibanez, Patricio
    Lubascher, Jaime
    Figueroa, Carolina
    Flores, Lilian
    Kronberg, Udo
    Pizarro, Gonzalo
    Fluxa, Daniela
    REVISTA MEDICA DE CHILE, 2018, 146 (11) : 1241 - 1251
  • [7] Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (02) : 369 - 370
  • [8] Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease
    Munoz Villafranca, M. D. C.
    Merino, O.
    Gomez, L.
    Higuera, R. O.
    Arreba, P.
    Nagore, D.
    Ruiz-Arguello, B.
    Gorostiza, I.
    Lopez, M. L.
    Ortiz de Zarate, J.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1570 - I1570
  • [9] Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment
    Krajcovicova, A.
    Batovsky, M.
    Gregus, M.
    Hlista, M.
    Durina, J.
    Leskova, Z.
    Sturdik, I
    Gojdic, M.
    Jalali, Y.
    Koller, T.
    Toth, J.
    Huorka, M.
    Hlavaty, T.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (04) : 465 - 470
  • [10] Longer Duration of Response With Proactive Therapeutic Drug Monitoring for Infliximab but Not for Vedolizumab Treatment in Patients With Inflammatory Bowel Disease
    Al Yassin, Sarmed
    Spataro, Joseph
    Kang, Le
    Gaidos, Jill
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S359 - S359
12345